Lilly To Continue Development Of Enzastaurin Despite Termination Of Glioblastoma Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Company remains optimistic and will pursue other indications, Lilly told “The Pink Sheet” DAILY.
You may also be interested in...
NeoPharm Suspends Glioblastoma Trials Following Disappointing Phase III Results
Firm seeks meeting with FDA to determine path forward.
Lilly To Include Biomarkers In Phase III Evaluation Of Enzastaurin
The firm has initiated Phase III trials of the oral serine-threonine kinase inhibitor to treat non-Hodgkin’s lymphoma and glioblastoma.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.